FY2026 Earnings Estimate for ACRS Issued By HC Wainwright

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Investment analysts at HC Wainwright raised their FY2026 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will earn ($0.52) per share for the year, up from their previous forecast of ($0.53). HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. The business had revenue of $1.30 million during the quarter, compared to analysts’ expectations of $2.07 million.

ACRS has been the subject of a number of other reports. Wall Street Zen cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Craig Hallum initiated coverage on shares of Aclaris Therapeutics in a research note on Friday, January 30th. They set a “buy” rating and a $10.00 price target on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $9.80.

Aclaris Therapeutics Stock Down 5.7%

ACRS opened at $3.66 on Wednesday. Aclaris Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.89. The company has a market cap of $441.40 million, a P/E ratio of -6.91 and a beta of 0.88. The firm’s 50-day moving average price is $3.37 and its 200-day moving average price is $2.75.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ACRS. Millennium Management LLC boosted its position in Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares during the last quarter. Geode Capital Management LLC raised its position in Aclaris Therapeutics by 108.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock worth $3,501,000 after buying an additional 1,282,042 shares during the last quarter. Kotler Kevin purchased a new position in Aclaris Therapeutics during the 4th quarter worth approximately $5,135,000. Palo Alto Investors LP lifted its stake in Aclaris Therapeutics by 12.7% during the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock valued at $2,977,000 after acquiring an additional 176,812 shares during the period. Finally, State Street Corp boosted its holdings in shares of Aclaris Therapeutics by 35.3% in the 4th quarter. State Street Corp now owns 1,506,403 shares of the biotechnology company’s stock valued at $4,534,000 after acquiring an additional 393,257 shares during the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.